Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market

Strive, in a statement, said it was disappointed by the ruling, especially since some state attorneys general had questioned the drug makers' efforts to defeat the claims. Strive said it was confident of its position and was evaluating options, including an appeal.

Lilly, in a statement, said “this meritless claim should have never been brought against Lilly” and that the court’s ruling “confirms that companies mass compounding tirzepatide are violating the law.”

Novo, in a statement, said it is “pleased with the court's decision to dismiss all claims against Novo Nordisk” and that the company remains focused on its mission.

Alvarez said Strive failed to plausibly allege a product market because compounded GLP-1 drugs are available only when a physician determines a branded drug cannot meet a patient's specific medical needs, making the products not reasonably interchangeable.